KetamineOne Capital Archives

KetamineOne Reports Fiscal Q1 2022 Financials: $2.0 Million In Revenue

KetamineOne Capital (NEO: MEDI) released this morning its financial reports for the fiscal quarter ended October 31, 2021. The firm managed

KetamineOne Capital (NEO: MEDI) has officially begun its research programs. The firm this morning announced the inaugural launch of not

Ketamine continues to be a hot topic in terms of clinical trials, with KGK Science, a subsidiary of KetamineOne Capital

KetamineOne Capital (NEO: MEDI) is evidently looking to expanding its service offerings. The firm this morning revealed that it has

KetamineOne Capital (NEO: MEDI) has continued to expand its presence across North America. The firm this morning announced that it

KetamineOne Capital (NEO: MEDI) is expanding its current offerings for veteran-focused multidisciplinary clinics. The company has added a total of

KetamineOne Capital Ltd. (NEO: MEDI) is a Vancouver-based wellness company with a focus on becoming the North American leader in

KetamineOne Capital (NEO: MEDI) appears to be taking a rather novel approach to psychedelic treatments. The firm this morning revealed

KetamineOne Capital (NEO: MEDI) this morning announced that its wholly-owned subsidiary, KGK Science, has hit certain milestones related to expanding